• Users Online: 132
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2011  |  Volume : 2  |  Issue : 2  |  Page : 3

Statins; a double weapon in treating dyslipidemic osteoporotic menopausal type 2 diabetic women


1 Department of Internal Medicine. Alexandria University, Alexandria, Egypt
2 Department of Clinical Pathology Alexandria University, Alexandria, Egypt
3 Department of Gynecology & Obstetrics, Alexandria University, Alexandria, Egypt

Correspondence Address:
F E Amara
Emeritus Professor of Internal Medicine, Unit of Diabetes & Metabolism, Department of Internal Medicine, Alexandria University, Alexandria, Egypt

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Recent reports have suggested the possible beneficial role of 3-hydroxy-3 methyl glutaryl Coenzyme-A (HMGCo-A) reductase inhibitors (Statins) in the management of osteoporosis. The aim of this work was to study the effect of statins; simvastatin and pravastatin, on bone mineral density (BMD) of dyslipidemic postmenopausal females with type 2 diabetes mellitus (T2DM) having osteoporosis. Thirty postmenopausal dyslipidemic type 2 diabetes females with no history of any disease or drug that can affect bone metabolism, were included in this study and classified into 2 groups. Group I received simvastatin 40 mg daily and group II received pravastatin 40mg daily, both for 6 months. Both, serum osteocalcin (a marker of bone formation) and urinary deoxypyridinoline (DPD) (a marker of bone resorption) were measured. Dual Energy X-ray Absorptiometry (DEXA) was used to assess BMD at 2 sites; the forearm (peripheral site) and the second & third lumbar vertebrae (axial site). Serum levels of osteocalcin and the BMD revealed significant increase and the urinary levels of DPD revealed significant decrease after 6 months of simvastatin therapy in group I, with mild change in the same parameters in group II, after 6 months of pravastatin administration. Yet these differences did not reach statistical significance. Our results confirmed the beneficial role of simvastatin in type 2 diabetes women with osteoporosis. However, further studies are needed to recognize the best effective dose as well as the possibility of using statins in combination with other currently used drugs in the treatment of osteoporosis.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed752    
    Printed62    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal